Advertisement
UK markets close in 3 hours 39 minutes
  • FTSE 100

    8,236.09
    +30.98 (+0.38%)
     
  • FTSE 250

    20,461.60
    +80.55 (+0.40%)
     
  • AIM

    774.61
    -2.89 (-0.37%)
     
  • GBP/EUR

    1.1828
    -0.0006 (-0.05%)
     
  • GBP/USD

    1.2688
    -0.0034 (-0.27%)
     
  • Bitcoin GBP

    52,140.50
    +857.44 (+1.67%)
     
  • CMC Crypto 200

    1,379.55
    -3.12 (-0.23%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • CRUDE OIL

    81.70
    +0.13 (+0.16%)
     
  • GOLD FUTURES

    2,353.90
    +7.00 (+0.30%)
     
  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     
  • HANG SENG

    18,335.32
    -95.07 (-0.52%)
     
  • DAX

    18,154.62
    +86.71 (+0.48%)
     
  • CAC 40

    7,640.69
    +70.49 (+0.93%)
     

Agenus Announces Virtual Annual Shareholders Meeting

LEXINGTON, Mass., June 04, 2024--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.

Webcast Information:

Date: Tuesday, June 11, 2024

ADVERTISEMENT

Time: 10:30 a.m. ET

A live webcast and replay will be accessible on the Company’s website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2024.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604262147/en/

Contacts

Investor
917-362-1370
investor@agenusbio.com

Media
612-839-6748
communications@agenusbio.com